AMAGINE-3: A phase 3 study of efficacy and safety of brodalumab compared with placebo and ustekinumab in moderate to severe plaque psoriasis subjects - 09/05/15
Bruce Strober, University of Connecticut School of Medicine and Probity Medical Research, Farmington, CT, United States; Richard Langley, Eastern Canada Cutaneous Research Associates Limited, Halifax, Nova Scotia, Canada; Tomasz Blicharski, Lubelskie Centrum Diagnostyczne, Swidnik, Poland; Carle Paul, Paul Sabatier University, Toulouse, France; Jean-Philippe Lacour, Center Hospitalier Universitaire Archet, Nice, France; Stephen Tyring, Center for Clinical Studies, Houston, TX, United States; Leon Kircik, Icahn School of Medicine at Mount Sinai and DermResearch, Louisville, KY, United States; Sergio Chimenti, University of Rome Tor Vergata, Rome, Italy; Kristina Callis Duffin, University of Utah Medical Center, Salt Lake City, UT, United States; Jerry Bagel, The Psoriasis Treatment Center of Central New Jersey, East Windsor, NJ, United States; John Koo, University of California, San Francisco, San Francisco, CA, United States; Gary Aras, Amgen Inc, Thousand Oaks, CA, United States; Yifei Shi, Amgen Inc, Thousand Oaks, CA, United States
Le texte complet de cet article est disponible en PDF.| Amgen Inc funded this study. Brodalumab is being codeveloped by Amgen Inc and AstraZeneca/MedImmune. |
Vol 72 - N° 5S1
P. AB224 - mai 2015 Retour au numéro
Article précédent
- Adherence to biologic treatment in patients with moderate to severe psoriasis
- An interesting case of leflunomide-induced pustular psoriasis in a patient with rheumatoid arthritis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?